AMA takes on generics and CME
The AMA's House of Delegates voted on measures including support for a ban on "pay-for-delay" deals and a recommendation that docs keep the the industry and CME separate.
View ArticleTeva says it will cut costs and innovate more
The drugmaker told investors Tuesday that generics will remain its standby, but novel therapeutic entities are also in its future.
View ArticleCompany news: AstraZeneca, Novartis, Teva
AstaZeneca avoids a Lipitor moment, FDA approves Novartis med for Cushing's, and Teva ventures into South Korea. Plus: a closer look at health exchanges
View ArticleStudy finds docs suceptible to lunches, patient demands for branded drugs
Internists and small-office practitioners are also more likely to prescribe branded drugs than their professional peers.
View ArticleBusiness briefs: Élan, Teva
A buyout offer upsets Elan's post-Tysabri plans, Takeda and Affymax recall Omontys.
View ArticleCourt could punt "Pay for Delay" back to Congress
Eight members of the Supreme Court heard testimony in the case of FTC v. Actavis this morning, and the fate of so-called "pay for delay" settlements hangs in the balance.
View ArticleSuccess in emerging markets hinges on broad network
Execs told Booz & Co researchers that the relationships web in emerging markets needs to be deeper than one-on-one sales pitches.
View ArticleBusiness Briefs: GSK, Astellas, Vertex and Orexigen
GSK and Astellas kick off the race for a new anemia treatment; Orexigen's CEO joins PhRMA; BMS and Merck team up in a hep.-C clinical trial; Novartis lands glaucoma approval; Ireland starts naming...
View ArticleStudies show cheaper drugs don't add up to greater use
Two studies released show that the story behind lower consumer healthspend isn't about generics improving health.
View ArticleBusiness briefs: Angelina Jolie, adherence, Sanofi, Teva, AbbVie
Jolie takes on cancer awareness role, researchers identify another adherence gap, Sanofi gets slapped for scare tactics, Teva may compete for Adcock, AbbVie R&D chief leaves
View ArticleBusiness briefs: Pfizer, BMS, CMS, Sanofi
Pfizer cuts 136 workers loose in Ireland, BMS is investing in heart failure treatments, CMS has an official new leader, and Sanofi's iBGStar may have a competitor.
View ArticleBusiness Briefs: Amgen and Astellas; GSK; Teva; Novo; Livestrong
Amgen and Astellas team up to take on Japan; GSK acquires Swiss vaccine developer's innovative platform; Ireland makes generic switches easier; Novo backs wet AMD therapy; Nike ditches Livestrong
View ArticleBusiness briefs: AbbVie, Teva, HIV, Diabetes, iPhone
AbbVie lays off 100 R&D staff; Teva looks to expand Copaxone footprint; researchers crack HIV protein code; monitors may be misleading diabetics and a prototype sensor turns iPhones into virus...
View ArticlePill-plus value adds beat brand names in the age of ACOs
The effectiveness of new drugs is in decline, says an analysis, and researchers say comparative studies should look beyond efficacy measures.
View ArticleBusiness briefs: Boehringer Ingelheim, Teva, Medicare
Good and bad news about Pradaxa; Plan B decision not deemed a big threat to Teva's sales; Study says Medicare patients more likely to receive brand-name medications than VA patients
View ArticlePay-for-delay deals can go on, Court rules, but not without legal risk
The Supreme Court split the baby on "pay-for-delay" settlements, allowing them to continue but opening manufacturers that make them up to lawsuits.
View ArticleResearchers spot $213B of wasteful drug spending
For a country bent on healthcare cost control, findings represent an opportunity: authors say nearly 8% of the nation's total outlay could have been avoided.
View ArticleSandoz readies Enbrel biosimilar for testing
The drug maker says it expects to use the Phase III clinical trial data to back applications in the EU and the US (when it gets a pathway setup).
View ArticleBusiness briefs: Roche, WellPoint, Bayer, Takeda, Allergan
A JAMA article says prostate cancer patients are getting treatments they don't need; Roche and AstraZeneca will share safety data; WellPoint gives cost sharing a new spin; Bayer seeks to boost its...
View Article
